// App-Quantinova.ai

P426 : The Differences in Efficacy and Tolerability of Nintedanib Based on the Severity of Idiopathic Pulmonary Fibrosis

Researchers

Presenter

  • M. Kato

Principal Investigators

  • S. Soma

  • Y. Arai

  • S. Nakazawa

  • H. Motomura

  • Y. Ochi

  • J. Watanabe

  • I. Sumiyoshi

  • H. Ihara

  • K. Kadoya

  • S. Togo

  • S. Sasaki

  • K. Takahashi

Medical Centers

  • Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Idiopathic pulmonary fibrosis

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved